XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue        
Total revenue $ 222,471,000 $ 239,572,000 $ 659,599,000 $ 678,103,000
Expenses        
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) [1] 163,126,000 181,761,000 493,071,000 521,748,000
Selling, general and administrative expenses [1] 51,292,000 52,366,000 152,582,000 151,749,000
Depreciation and amortization expenses 14,859,000 14,534,000 44,962,000 46,130,000
Loss on disposal of assets 0 0 0 6,447,000
Loss on extinguishment of debt, net 0 4,789,000 0 4,789,000
Goodwill impairment 0 0 0 215,100,000
Change in fair value of contingent consideration and indemnification asset (225,000) 2,570,000 (819,000) (492,000)
Total operating expenses 229,052,000 256,020,000 689,796,000 945,471,000
Operating loss (6,581,000) (16,448,000) (30,197,000) (267,368,000)
Interest income 120,000 1,159,000 311,000 2,634,000
Interest expense (6,367,000) (7,416,000) (18,978,000) (19,987,000)
Impairment of equity method investments 0 0 0 (47,133,000)
Gain from equity method investees 63,000 (13,717,000) 12,725,000 11,014,000
Gain on transfer of membership 0 0 22,969,000 0
Loss on repayment of debt 0 0 (19,158,000) 0
Other income (expense), net (41,000) (110,000) (73,000) 174,000
Loss from continuing operations before income taxes (12,806,000) (36,532,000) (32,401,000) (320,666,000)
Provision (benefit) for income taxes 234,000 503,000 936,000 (3,131,000)
Loss from continuing operations (13,040,000) (37,035,000) (33,337,000) (317,535,000)
Income (loss) from discontinued operations, net of tax [2] 0 (1,135,000) 1,383,000 (2,908,000)
Net loss (13,040,000) (38,170,000) (31,954,000) (320,443,000)
Net loss attributable to non-controlling interests 0 (822,000) 0 (822,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic (13,040,000) (37,348,000) (31,954,000) (319,621,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted $ (13,040,000) $ (37,348,000) $ (31,954,000) $ (319,621,000)
Loss per common share        
Continuing operations, basic (in dollars per share) $ (0.15) $ (0.43) $ (0.39) $ (3.84)
Continuing operations, diluted (in dollars per share) (0.15) (0.43) (0.39) (3.84)
Discontinued operations, basic (in dollars per share) 0 (0.01) 0.02 (0.03)
Discontinued operations, diluted (in dollars per share) 0 (0.01) 0.02 (0.03)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) (0.15) (0.44) (0.37) (3.87)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) $ (0.15) $ (0.44) $ (0.37) $ (3.87)
Weighted-average common shares outstanding        
Basic (in shares) 85,800 85,172 85,306 82,615
Diluted (in shares) 85,800 85,172 85,306 82,615
Comprehensive loss        
Net loss $ (13,040,000) $ (38,170,000) $ (31,954,000) $ (320,443,000)
Other comprehensive loss, net of taxes, related to:        
Foreign currency translation adjustment 4,000 71,000 (85,000) (86,000)
Total comprehensive loss (13,036,000) (38,099,000) (32,039,000) (320,529,000)
Total comprehensive loss attributable to non-controlling interests 0 (822,000) 0 (822,000)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. (13,036,000) (37,277,000) (32,039,000) (319,707,000)
Transformation services        
Revenue        
Total revenue [1] 2,075,000 4,807,000 4,984,000 10,800,000
Platform and operations services        
Revenue        
Total revenue [1] $ 220,396,000 $ 234,765,000 $ 654,615,000 $ 667,303,000
[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.
[2] Includes $1.9 million gain on disposal of discontinued operations for the nine months ended September 30, 2021